HOXVITARC

Hoxvitarc is a UK-based biotechnology company dedicated to the development of targeted cancer therapies that exploit the dysregulation of HOX genes. The company's proprietary technology focuses on disrupting the interaction between HOX transcription factors and their cofactor, PBX, a mechanism essential for the survival of many cancer cells. Their lead program, HXR9, is a first-in-class peptide antagonist that has demonstrated the ability to induce apoptosis across a broad spectrum of solid and hematological malignancies. By targeting a fundamental driver of oncogenesis that is largely silent in adult tissues, Hoxvitarc aims to provide potent anti-tumor activity with minimal toxicity. The company is currently advancing its pipeline toward clinical evaluation in indications such as melanoma, prostate cancer, and acute myeloid leukemia.